Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for ELAN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -74.00M
March 31, 2026 -65.00M
December 31, 2025 -18.00M
September 30, 2025 -153.00M
June 30, 2025 -156.00M
March 31, 2025 52.00M
December 31, 2024 -32.00M
September 30, 2024 -1.34B
June 30, 2024 -93.00M
March 31, 2024 -27.00M
December 31, 2023 -139.00M
September 30, 2023 -157.00M
June 30, 2023 39.00M
March 31, 2023 174.00M
December 31, 2022 -84.00M
September 30, 2022 -170.00M
June 30, 2022 -95.00M
Date Value
March 31, 2022 -200.00M
December 31, 2021 44.00M
September 30, 2021 231.00M
June 30, 2021 -67.00M
March 31, 2021 2.00M
December 31, 2020 -18.30M
September 30, 2020 4.068B
June 30, 2020 7.30M
March 31, 2020 896.60M
December 31, 2019 -6.20M
September 30, 2019 -48.80M
June 30, 2019 89.70M
March 31, 2019 -339.50M
December 31, 2018 -362.40M
September 30, 2018 450.90M
June 30, 2018 -47.20M
March 31, 2018 -76.50M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Zoetis, Inc. -813.00M
Eli Lilly & Co. 8.426B
ANI Pharmaceuticals, Inc. -4.647M
EyePoint, Inc. 19.99M
Amylyx Pharmaceuticals, Inc. 1.479M